Teva Pharmaceutical Industries Limited (NYSE:TEVA) and Glenmark Pharmaceuticals have agreed to pay $225 million and $30 million respectively to settle charges related to price fixing of medications, including a generic cholesterol drug, pravastatin. Both companies will divest their versions of pravastatin as part of the settlement. Teva has also committed to donating $50 million worth of two generic drugs affected by price fixing to humanitarian organizations. The settlements are structured as deferred prosecution agreements, meaning that Teva and Glenmark will avoid trial or criminal punishment if they comply with the terms outlined in the agreements.